Almirall SA ((GB:0O9B)), Almirall ((DE:E2Z)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Almirall S.A. is conducting a study titled ‘Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting – Light Version.’ The study aims to explore the connection between clinical symptoms and quality of life in patients with moderate to severe plaque psoriasis treated with Tildrakizumab, a drug administered in routine clinical settings.
The intervention being tested is Tildrakizumab, a drug designed to treat moderate to severe plaque psoriasis. It is used in real-world clinical practice to assess its impact on patient wellbeing and quality of life.
This observational study follows a cohort model with a prospective time perspective. It does not involve random allocation or masking, focusing instead on observing the outcomes of patients receiving the drug in a real-world setting.
The study began on April 4, 2024, with the primary completion date yet to be announced. The last update was submitted on June 23, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
The update on this study could influence Almirall’s stock performance and investor sentiment, as successful results may enhance the company’s market position in the psoriasis treatment sector. Investors should also consider the competitive landscape, as advancements in psoriasis treatments are ongoing across the industry.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.